Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 58 for “"MarketScan®"”.

  1. Data mining techniques for temporal point processes applied to insurance claims data

    … of new methods for data extracted from the MarketScan® database. We summarize the results of applying popular kernels, as well as new kernels constructed specifically for this task, for support vector machines on data derived from this database. We were able to predict patients at risk of …

    colostate Repository record for Data mining techniques for temporal point processes applied to insurance claims data (opens in a new tab)

  2. Evaluating Methods to Estimate United States Multiple Sclerosis Prevalence from Administrative Health Claims Data

    … with MS were identified in AHC data from IBM® MarketScan® Research Databases – one of the largest samples of employer-sponsored health plan data comprised of over 250 million unique patients since 1995.6 Multiple Sclerosis patients were identified based on inpatient, outpatient, and …

    washington Repository record for Evaluating Methods to Estimate United States Multiple Sclerosis Prevalence from Administrative Health Claims Data (opens in a new tab)

  3. Biosimilars in the United States: Market Dynamics and Patient Out-of-Pocket Costs

    … Set (5% sample) for Medicare and the MerativeTM MarketScan® Commercial Database for the commercial population were used as data sources, using price and volume (number of claims) for the following biologics: filgrastim, rituximab, infliximab, trastuzumab, pegfilgrastim, epoetin alfa, bevacizumab, …

    washington Repository record for Biosimilars in the United States: Market Dynamics and Patient Out-of-Pocket Costs (opens in a new tab)

  4. Cardiovascular Disease In Cancer Survivors

    … CVD or cancer. For Manuscript 2, we used the Marketscan® administrative healthcare claims databases to estimate the cardiovascular risk associated with the use of two hormone therapies, aromatase inhibitors (with ovarian suppression) and tamoxifen in premenopausal female breast cancer …

    umn Repository record for Cardiovascular Disease In Cancer Survivors (opens in a new tab)

  5. The impact of cost sharing on adherence to ibrutinib for patients with diffuse large B-cell lymphoma

    … We conducted a retrospective study using MarketScan® commercial and Medicare supplemental claims to identify adults with DLBCL who initiated ibrutinib therapy between October 1, 2015 and December 31, 2018 with > 6 months of insurance coverage before and after initiation. Primary outcomes …

    washington Repository record for The impact of cost sharing on adherence to ibrutinib for patients with diffuse large B-cell lymphoma (opens in a new tab)

  6. Prescribing of Alzheimer’s Disease Treatments by Provider Type and Geographic Region: A Comparison among Physicians, Nurse Practitioners, and Physician Assistants

    … conducted a retrospective cohort study using IBM MarketScan® commercial and Medicare supplemental claims to examine unique AD prescriptions prescribed between January 1, 2016, and December 31, 2019. Food and Drug Administration (FDA) indicated AD prescriptions were identified and prescribing …

    washington Repository record for Prescribing of Alzheimer’s Disease Treatments by Provider Type and Geographic Region: A Comparison among Physicians, Nurse Practitioners, and Physician Assistants (opens in a new tab)

  7. Use of Bevacizumab for Newly Diagnosed Ovarian Cancer: A National Analysis

    … OC from 2008 to 2016 through the Truven Health MarketScan® database. Of these, women who underwent cancer-directed surgery and platinum-based chemotherapy within 6 months of diagnosis were included (N=8109). The proportion of women receiving BEV was calculated and multivariate logistic …

    washington Repository record for Use of Bevacizumab for Newly Diagnosed Ovarian Cancer: A National Analysis (opens in a new tab)

  8. The Utilization and Safety of Per Oral Endoscopic Myotomy (POEM) for Achalasia in the US

    … with POEM, PD, or LHM (2010-2017) using the MarketScan® claims databases. Administrative codes used to measure POEM were validated in an institutional cohort using gold standard chart abstraction. We compared frequencies of perforation requiring intervention and healthcare utilization in the …

    washington Repository record for The Utilization and Safety of Per Oral Endoscopic Myotomy (POEM) for Achalasia in the US (opens in a new tab)

  9. Antiepileptic Drug Switching and Epilepsy-related Events in Subjects with Epilepsy: A Case-Control Analysis of Health Insurance Claims Data

    … using recent claims data from the Truven Health MarketScan® Commercial Database. Cases and matched controls with a diagnosis of epilepsy were identified using emergency services and inpatient visits or outpatient visit claims, respectively. Cases and controls were matched using a 1:1 ratio for …

    washington Repository record for Antiepileptic Drug Switching and Epilepsy-related Events in Subjects with Epilepsy: A Case-Control Analysis of Health Insurance Claims Data (opens in a new tab)

  10. Nusinersen Treatment and Healthcare Costs in Spinal Muscular Atrophy

    … a retrospective cohort study using IBM® MarketScan® to identify patients with ≥2 SMA diagnoses ≥30 days apart and ≥30 days of follow-up after their index date. The index date for nusinersen-treated patients was their first nusinersen administration after January 2017, and follow-up ended …

    washington Repository record for Nusinersen Treatment and Healthcare Costs in Spinal Muscular Atrophy (opens in a new tab)

  11. INCREASED HEALTHCARE UTILIZATION FOR MEDICAL COMORBIDITIES PRIOR TO COLORECTAL SURGERY IS ASSOCIATED WITH IMPROVED POSTOPERATIVE OUTCOMES

    … colectomy from 2010-2014 were identified in MarketScan®, a large, aggregated, private payer database. Patients were included if they could be matched to a preoperative surgical clinic visit within 90 days of an operative intervention by the same surgeon. The explanatory variable of interest …

    jhu Repository record for INCREASED HEALTHCARE UTILIZATION FOR MEDICAL COMORBIDITIES PRIOR TO COLORECTAL SURGERY IS ASSOCIATED WITH IMPROVED POSTOPERATIVE OUTCOMES (opens in a new tab)

  12. Comparing Healthcare Resource Utilization and Costs in HFPEF patients using SGLT2-inhibitor Combination Treatments: A Retrospective Claims Analysis

    … a retrospective cohort study using the Merative™ MarketScan® commercial and Medicare databases from 2019 to 2023 to compare HCRU and costs in adult patients (≥18 years) with HFpEF initiating SGLT2i+MRA vs. SGLT2i+ARNI. Patients required SGLT2i usage and continuous enrollment for 12 months pre- and …

    washington Repository record for Comparing Healthcare Resource Utilization and Costs in HFPEF patients using SGLT2-inhibitor Combination Treatments: A Retrospective Claims Analysis (opens in a new tab)

  13. Risk of Depressive or Anxiety Disorders in Commercially Insured Patients with Non-Hodgkin Lymphoma (NHL) in the US: A Retrospective Analysis

    … cohort analysis was conducted using MarketScan® claims data from 2008 to 2015. Patients with NHL were identified by ICD-9 code and matched on a 1:1 ratio to cancer-free controls using propensity scores generated from age, region, and Charlson comorbidity index (CCI) score. Incidence …

    washington Repository record for Risk of Depressive or Anxiety Disorders in Commercially Insured Patients with Non-Hodgkin Lymphoma (NHL) in the US: A Retrospective Analysis (opens in a new tab)

  14. Assessing the Potential Health Impact of Delays in Access to Innovative Medicines in Low- and Middle-income Countries: A Modelling Approach in Colombia

    … domestic market (SISMED Spanish acronym) and MarketScan® data set for the United States. The potential health outcomes lost were calculated as the health outcome lost due to delayed approval and uptake. Finally, a cost analysis was included for both countries. Results: There were identified …

    washington Repository record for Assessing the Potential Health Impact of Delays in Access to Innovative Medicines in Low- and Middle-income Countries: A Modelling Approach in Colombia (opens in a new tab)

  15. Demographic, Geographic, and Clinical Characteristics Associated with Receipt of Influenza Outpatient Oral Antiviral Treatment in Commercially Insured US Patients: An Exploration of Potential Health Disparities

    … conducted a retrospective cohort study using IBM Marketscan® commercial claims to identify unique influenza cases between May 1, 2016 and April 30, 2019. For each annual cohort, odds of OOAT were determined for association with age, sex, level of rurality, region, health plan type, employment …

    washington Repository record for Demographic, Geographic, and Clinical Characteristics Associated with Receipt of Influenza Outpatient Oral Antiviral Treatment in Commercially Insured US Patients: An Exploration of Potential Health Disparities (opens in a new tab)

  16. Use of statins and the development of incident diabetes mellitus : a retrospective cohort study

    … that utilized data from the Thomson Reuters MarketScan® Commercial Claims Database for the period of 2003 - 2004. The study population included new statin users who were aged 20 - 63 years at index and who do not have a history of diabetes. Among the study population (N=116,224), 6.5% (or …

    texas Repository record for Use of statins and the development of incident diabetes mellitus : a retrospective cohort study (opens in a new tab)

  17. Treatment Patterns & Clinical Effectiveness of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Type 2 Diabetes

    … utilizing US claims data from Merative™ MarketScan® Research Databases (2014-2023). Propensity score matching (1:1, PSM) was used to baseline covariate differences between GLP-1 RA and SGLT2i users. Adherence was measured by using PDC, and discontinuation was operationalized as a ≥ 90-day …

    houston Repository record for Treatment Patterns & Clinical Effectiveness of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Patients with Type 2 Diabetes (opens in a new tab) Embargoed until 2027-12-01

  18. Association between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products

    … individual-level claims data from IBM MarketScan®. Analyses included all outpatient and prescription claims for branded filgrastim and biosimilar filgrastim (filgrastim-sndz) from January 1, 2014 to December 31, 2017. Interventions. The September 2015 launch of filgrastim-sndz. Main …

    jhu Repository record for Association between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products (opens in a new tab)

  19. Comparative safety of smoking cessation pharmacotherapies

    … the British Columbia Ministry of Health and U.S. MarketScan® databases. Outcomes: The primary safety outcome was a composite of cardiovascular hospitalizations. Secondary safety outcomes included: all-cause mortality, a composite of neuropsychiatric hospitalizations, and individual components of …

    ubc Repository record for Comparative safety of smoking cessation pharmacotherapies (opens in a new tab) Download PDF for Comparative safety of smoking cessation pharmacotherapies (opens in a new tab)

  20. Predicting Wildfire Smoke-Associated Acute Care Utilization in Washington State Using Observed PM2.5 Data

    … claims data (2015–2018) from the Merative MarketScan® Research Databases to identify a study population of 83,350 enrollees with active asthma or COPD diagnoses. We trained LightGBM gradient boosting frameworks to predict cardiorespiratory ED visits and inpatient admissions within one week …

    washington Repository record for Predicting Wildfire Smoke-Associated Acute Care Utilization in Washington State Using Observed PM2.5 Data (opens in a new tab)

Page 1 of 3